Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Enveric Biosciences Inc
(NQ:
ENVB
)
0.9298
UNCHANGED
Streaming Delayed Price
Updated: 3:59 PM EDT, May 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Enveric Biosciences Inc
< Previous
1
2
3
Next >
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023
March 26, 2024
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease
March 19, 2024
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets
March 12, 2024
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds
February 29, 2024
From
Enveric Biosciences
Via
Business Wire
Medical Breakthrough Stocks Under $1: OCGN, VERO, RSCI, VTAK, ENVB
February 28, 2024
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property
February 23, 2024
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders
February 21, 2024
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series
January 03, 2024
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-Market
December 29, 2023
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series
December 28, 2023
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373
December 27, 2023
From
Enveric Biosciences
Via
Business Wire
5 Biotech stocks tapping into unmet mental health treatment needs
December 20, 2023
Here are five biotech companies currently working on drug candidates that tap into this soaring need for life-saving mental health treatments.
Via
MarketBeat
Enveric Biosciences to Participate in Biotech Showcase 2024 During “J.P. Morgan Week 2024”
December 20, 2023
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds
December 05, 2023
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives
November 29, 2023
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry
November 27, 2023
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences Announces Presentation of Two Posters at Canadian Chemical Engineering Conference (CSChE 2023)
November 24, 2023
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences Reports Third Quarter 2023 Corporate and Financial Results
November 13, 2023
From
Enveric Biosciences, Inc.
Via
Business Wire
Enveric Biosciences to Present at the Centurion One 5th Global Summit
October 20, 2023
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373, a Next Generation Psilocin Prodrug Targeting Psychiatric Disorders
October 18, 2023
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences Announces Two Poster Presentations at the 6th Neuropsychiatric Drug Development Summit
October 11, 2023
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences Announces its Psybrary™ Portfolio Now Totals Over 1000 Psychedelic-Inspired Therapeutic Candidates
October 03, 2023
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences Announces Publication of a Paper Describing a Novel Bioproduction Platform for Psychedelic-Inspired Drug Discovery in the Journal of Biological Chemistry
September 27, 2023
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences Expands IP Portfolio with New U.S. Patent for Novel Carboxylated Psilocybin Derivatives Supporting its EVM301 Series of Drug Candidates
September 20, 2023
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences to Present Poster Highlighting EVM301 Series at the International Conference on Molecular Biology and Biochemistry 2023
September 18, 2023
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences Files Provisional Patent Application for AI-based Computational Methods for Identifying and Optimizing Novel Tryptamine Derivatives
September 11, 2023
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences Announces New U.S. Patent for C4-Carboxylic Acid-Substituted Tryptamine Derivatives
September 05, 2023
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences to Present at H.C. Wainwright 25th Annual Global Conference
August 30, 2023
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences Strengthens Intellectual Property Portfolio with New U.S. Patent for Tryptamine-derived Prodrugs
August 28, 2023
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program
August 21, 2023
From
Enveric Biosciences
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.